 | Up a level |
Meijer, A J M; Diepstraten, F A; Langer, T; Broer, L; Domingo, I K; Clemens, E; Uitterlinden, A G; de Vries, A C H; van Grotel, M; Vermeij, W P; Ozinga, R A; Binder, H; Byrne, J; van Dulmen-den Broeder, E; Garrè, M L; Grabow, D; Kaatsch, P; Kaiser, M; Kenborg, L; Winther, J F; ... (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), p. 64. Springer Nature 10.1038/s41698-021-00178-z
Lanvers-Kaminsky, C; Krefeld, B; Dinnesen, A G; Deuster, D; Seifert, E; Würthwein, G; Jaehde, U; Pieck, A C; Boos, J (2006). Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatric blood & cancer, 47(2), pp. 183-93. Hoboken, N.J.: Wiley-Liss 10.1002/pbc.20673
